NCT04975139

Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks

Recruiting now Last updated 2 February 2026

What this trial tests

trial testing RS-fMRI in Glioma in 96 participants. Currently enrolling.

Timeline

2 September 2020

Primary endpoint
31 October 2033

31 October 2033

Quick facts

Lead sponsor	Washington University School of Medicine
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	96
Start date	2 September 2020
Primary completion	31 October 2033
Estimated completion	31 October 2033
Sites	1 location across United States

Drugs / interventions tested

• RS-fMRI

Conditions studied

• Glioma — all drugs for Glioma →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neurocognitive decline after radiation therapy is one of the most concerning complication for brain tumor patients and neuro-oncologists. There are increasing technological advances in evaluating the brain's neural connections responsible for the neurocognitive processes. For example, resting-state functional MRI (RS-fMRI) is an advanced imaging method that can identify the spatiotemporal distribution of the intrinsic functional networks within the brain (also referred to as resting state networks (RSNs) without requiring specific tasks by the imaged participants. Although there is evidence that shows that avoidance of specific neural networks during radiation therapy planning can lead to improved preservation of neurocognitive function afterward, it is important to first identify the most vulnerable and clinically relevant RSNs that correspond to cognitive decline. In this study, the investigators will prospectively perform RS-fMRI and neurocognitive evaluation using the NIH Toolbox Cognitive Battery (NIHTB-CB) on patients with gliomas before and after radiation therapy to generate preliminary data on what RSNs are most vulnerable to radiation injury leading to cognitive decline. A benign brain tumor cohort will also be followed to serve as control. The investigators will also evaluate the feasibility of incorporating RS-fMRI with radiation planning software for treatment optimization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Neurocognitive and Resting-State Functional Magnetic Resonance Imaging Changes in Patients With Diffuse Gliomas After Chemoradiation Therapy.
   Liu Z, Mitchell TJ, Luo C, Park KY, et al · · 2025 · PMID 40107623 · DOI 10.1016/j.ijrobp.2025.03.017